Drug Profile
Research programme: cancer and autoimmune disorders imaging agents - ImaginAb/Duke-NUS
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Duke-NUS Graduate Medical School Singapore; ImaginAb Inc
- Class Antibody diagnostics; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Autoimmune-disorders(Diagnosis) in Singapore (Parenteral)
- 28 Jul 2018 No recent reports of development identified for research development in Cancer(Diagnosis) in Singapore (Parenteral)
- 10 Feb 2014 ImaginAb and the Duke-NUS Graduate Medical School Singapore (Duke-NUS) enter into a partnership to develop in vivo molecular imaging agents for cancer and autoimmune disorders